natgillin/translations-raw huggingface dataset:
The oligomer according to any one of embodiments 1 - 3, wherein, the first region is an antisense oligomer, which comprises a sequence which is complementary to a nucleic acid target. The oligomer according to embodiment 4, wherein the nucleic acid target is selected from the group consisting of a microRNA, a mRNA, 
Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da je ciljna nuklemska kiselina odabrana iz skupine koja se sastoji od mikroRNK, mRNK, IncRNK (duge nekodirajuće RNK), snRNK, snoRNK te virusne RNK.
The peptide of claim 1, wherein said peptide consists of the amino acid sequence of SEQ ID NO: 376 or 379. 
Peptid u skladu s patentnim zahtjevom 1, naznačen time što se navedeni peptid sastoji od aminokiselinskog slijeda SEQ ID NO: 194, 174, 178 ili 186.
The composition of the present invention can be administered, orally, topically, by inhalation, by suppository, intravenously, subcutaneously, or intramuscularly. 
Sastav za upotrebu temeljem zahtjeva 1, pri čemu se sastav daje, oralno, topikalno, inhalacijom, supozitorijem, intravenozno, potkožno ili intramuskularno.
The composition for use according to claim 23, wherein the therapeutically effective amount of crenolanib or a salt thereof is provided prophylactically at an effective amounts, from 50 to 500 mg per day, 100 to 450 mg per day, 200 to 400 mg per day, 300 to 500 mg per day, 350 to 500 mg per day, or 400 to 500 mg per day. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu se terapijski djelotvorna količina crenolaniba ili njegove soli daje profilaktički u djelotvornoj količini od 50 do 500 mg dnevno, od 100 do 450 mg dnevno, od 200 do 400 mg dnevno, od 300 do 500 mg dnevno, od 350 do 500 mg dnevno ili od 400 do 500 mg dnevno.
The antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof comprises a light chain sequence comprising the amino acid sequence of SEQ ID NO: 39 and wherein the light chain variable framework region comprises at least one amino acid modification, wherein the amino acid modification is an amino acid substitution or deletion, from the corresponding light chain variable framework region of the corresponding murine antibody of SEQ ID NO: 8. 
Protutijelo ili njegov fragment sukladno patentnom zahtjevu 1, naznačeno time da, protutijelo ili njegov fragment sadrži sekvencu lakog lanca koja sadrži aminokiselinsku sekvencu SEK ID BR: 39 pri čemu promjenjiva okvirna regija lakog lanca sadrži najmanje jednu modifikaciju amino kiseline iz odgovarajućeg promjenjive okvirne regije lakog lanca odgovarajućeg mišjeg protutijela. HR P20180858 T1
iii) C1-C10 alkoxy and iv) aryl optionally substituted with aryl optionally substituted with C1-C10 alkyl, heteroaryl optionally substituted with a C1-C10 alkyl group(s), 
atoma halogena, ii) C1-C10 alkila, iii) C1-C10 alkoksi i iv) arila, izborno supstituiranog s arilom izborno supstituiranim s C1-C10 alkilom, heteroarila, izborno supstituiranog s jednom ili više C1-C10 alkilnih skupina,
A composition comprising N-benzoyl-staurosporine as a solid, wherein at least 80% by weight of said solid N-benzoyl-staurosporine its crystalline form II according to claim 1 . 
Spoj, naznačen time, da sadrži N-benzoil-staurosporin kao krutinu, pri čemu je najmanje 80 masenih % od spomenute krutine N-benzoil-staurosporina u kristalnom obliku II prema zahtjevu 1.
The process according to claim 1, wherein mixed oxides containing both Mo and V; W and V or Mo; or W and V are used as a catalytic system to carry out the catalytic oxydehydrogenation. 
Postupak prema zahtjevima 1 do 10, naznačen time da miješani oksidi koji sadrže oboje Moi V, Wi Vili Mo, Wi V se koriste kao katalitički sustavi za provođenje katalitičke oksidehidrogenacije.
The apparatus according to claim 12, adapted to effect pyrolysis of the waste in the chamber at a temperature from 400-700° C. 
Uređaj prema zahtjevu 13, prilagođen za provođenje pirolize otpada na temperaturi od 400-700*C.
Blood samples are collected at baseline (2 days after the reception of the animals), and 50 days after the initiation of the diet. 
Krvni uzorci su sakupljeni kao bazalni (2 dana nakon primanja životinja), te 50 dana nakon početka dijete.
"Alkyl", "cycloalkyl", "alkenyl", "alkynyl", "aryl", "heteroaryl", "heterocycle" refers also to the corresponding "alkylene", "cycloalkylene", "alkenylene", "alkynylene", "arylene", "heteroarylene", "heterocyclene" which are formed by the removal of two hydrogen atoms. 
"Alk1l", "cikloalkil", "alkenil", "alkinil", "aril", "heteroaril", "heterocikl" također se odnosi na odgovarajući "alkilen", no" "cikloalkilen", "alkenilen", "alkinilen", "arilen", "heteroarilen", "heterocikl", koje se dobiva uklanjanjem dva vodikova atoma.
y is an amino acid other than Cys, and wherein said cyclic peptide consists of at least 16 and at most 25 amino acids and comprises one of amino acid sequences: 
€) yje aminokiselina koja nije Cys, 1 gdje navedeni ciklički peptid se sastoji od najmanje 16, a najviše 25 aminokiselina i ima aminokiselinski slijed
The present compositions may further include one or more additional excipients, such as Microcrystalline cellulose (MCC)TABULOSE® SC 200), Mg Stearate, Sodium Lauryl Sulfate (SLS) EMAL® 10Pwd HD, a polysorbate (such as, polysorbate 80), or a combination thereof, including all of these. 
Sastav prema patentnom zahtjevu 1., naznačen time da se nadalje sastoji od mikrokristalne celuloze (MCC), magnezijevog stearata, natrijevog lauril sulfata (SLS), polisorbata 80 ili neke kombinacije navedenog.
determining with the processor mechanism evidence of at least a first user mark in the detected first user marking cell based at least in part upon a degree of brightness similarity between: (a) at least a portion of the electronic image surrounding the indicium bounding the first user marking cell; and (b) at least a portion of the electronic image included inside the indicium bounding the first user marking cell; and determining with the processor mechanism evidence of at least a second user mark in the detected second user marking cell based at least in part upon a degree of brightness similarity between: (a) at least a portion of the electronic image surrounding the indicium bounding the second user marking cell; and (b) at least a portion of the electronic image included inside the indicium bounding the second user marking cell. 
određivanja procesorskim mehanizmom dokaza o u najmanju ruku prvoj korisničkoj oznaci u detektiranoj prvoj ćeliji za korisničku oznaku na temelju u najmanju ruku dijelom stupnja sličnosti svjetline između: (a) u najmanju ruku dijela elektronske slike koji okružuje bilješku koja omeđuje prvu ćeliju za korisničku oznaku; i (b) u najmanju ruku dijela elektronske slike koji se nalazi unutar bilješke koja omeđuje prvu ćeliju za korisničku oznaku; i određivanja procesorskim mehanizmom dokaza o u najmanju ruku drugoj korisničkoj oznaci u detektiranoj drugoj ćeliji za korisničku oznaku na temelju u najmanju ruku dijelom stupnja sličnosti svjetline između: (a) u najmanju ruku dijela elektronske slike koji okružuje bilješku koja omeđuje drugu ćeliju za korisničku oznaku; i (b) u najmanju ruku dijela elektronske slike koji se nalazi unutar bilješke koja omeđuje drugu ćeliju za korisničku oznaku.
Volume increase Spiral depth measured after 12 sec 
Spiralna dubina 12 sek. pripravljeno sa: šećerom
Experimental samples were incubated at 37° C. and the increase in absorbance at 234 nm was automatically recorded every is min for at least 1 h. 
Pokusni uzorci su inkubirani pri 372C 1 porast apsorpcije pri 234 nm je automatski zabilježen svakih 15 min tijekom najmanje 12h.
The sequences of substrate and target DNA were described in Nucleic Acid Research 1994, 22,1121. 
Sekvence supstratne i ciljne DNK su opisane u Nucleic Acid Research 22,1121 (1994).
The process of any of claims 22-27, further, after the forging step, comprising a step of preliminary heat treatment, preferably to a temperature of between 700 - 1100 °C or between 800 - 900 °C, which may include hydrogen diffusion treatment. 
Postupak prema bilo kojem od zahtjeva iz točke 21-26, nakon postupka kovanja, sastoji se od prethodnog postupka zagrijavanja najbolje na temperaturu između 700-1100°C ili između 800-900°C, koji može uključiti postupak razlijevanja/raspršivanja vodika.
A compound of Formula (I) according to claim 1 or claim 3, wherein 
Spoj Formule (I) u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3,
a time-frequency deinterleaver configured to time-frequency deinterleave constellation values corresponding to PLP data; a QAM demapper configured to demap the deinterleaved constellation values into cell words and to multiplex the demapped cell words into PLP data; 
QAM demaper konfiguriran za demapiranje raspletenih konstelacijskih vrijednosti u stanične riječi i za multipleksiranje demapiranih staničnih riječi u PLP podatke; dio za raspletanje bitova konfiguriran za raspletanje bitova multipleksiranih PLP podataka;
In any case, the bottom 28 will exert an axial compression force on the sealing member 11. 
U svakom slučaju, dno 28 će biti podvrgnuto sili aksijalnog stlačivanja na element za nepropusno zatvaranje 11.
In like manner to that described in Examples 1-3 the named compound was prepared from commercially available 4-chlorobenzophenone and resolved into its enantiomeric forms: 
Na sličan način s onim kao što je opisano u primjerima 1-3 napravljen je imenovani spoj iz komercijalno pristupačnog 4-klorobenzofenona i razloženo je u njegove enantiomerne oblike:
each LA is independently an unbranched or branched, linear alkyl having 1, 2, 3, or 4 C atoms wherein 1, 2 or 3 H atoms may be replaced by Hal; and each Hal is independently F, Cl, Br or I. 
LA je nerazgranati ili razgranati, linearni alkil koji ima 1, 2, 3, ili 4 C atoma pri čemu 1, 2 ili 3 H atoma mogu biti zamijenjeni sa Hal (npr., metil, etil, i trifluormetil); i Hal je F, Cl, Br ili I.
Use of Claim 56 or 73, wherein the pharmaceutical composition further comprises a therapeutic agent that does not antagonize IL-17 or IL-23 activity, wherein the therapeutic agent is capable of alleviating at least one symptom of the AOID or at least one side effect of the antagonist. 
Uporaba u skladu sa zahtjevom 56 ili 73, naznačena time, da farmaceutski pripravak nadalje sadrži terapeutsko sredstvo koje ne antagonizira djelovanje IL-17 ili IL-23, pri čemu je terapeutsko sredstvo sposobno ublažiti barem jedan simptom AQID ili barem jedno nuz-djelovanje antagonista,
A compound of formula (V), a salt, or stereoisomer thereof, 
Spoj formule (V), njegova sol ili njegov stereoizomer R>?
In some embodiments, the effective amount of time is about 2 to about 18 hours. 
Postupak iz zahtjeva 26, naznačen time da je učinkovita količina vremena 2 do 24 sata.
The composition of claim 6 or 7, wherein the polyolefin is a polypropylene grafted with acrylic acid (PP-g-AA). 
Pripravak u skladu s patentnim zahtjevom 6 ili 7, naznačen time što je poliolefin polipropilen s nakalemljenom akrilnom kiselinom (PP-g-AA).
The coal feeder system of claim 1, wherein a bridged material in at least one of the conical section and an exit section of the lock vessel and a packed material adjacent to the walls of the lock vessel are dispersed, allowing pulverized material to flow from the lock vessel to feed vessel. 
Sustav opskrbe ugljenom (100) prema zahtjevu 1, naznačen time, da su premošteni materijal u najmanje jednom konusnom odsječku i/ili u izlaznom odsječku od zatvorene posude kao i gusto pakirani materijal susjedan stijenkama zatvorene posude, raspršeni, dopuštajući raspršenom materijalu da struji iz zatvorene posude prema opskrbnoj posudi.
The term ‘first proximal end’ refers to the end of the first fragment (Tox A fragment) which is covalently linked to the second fragment (ToxB fragment) or covalently linked to a linker sequence between the first and second fragment and is closest to the second fragment in primary structure. 
(iv) drugi fragment ima drugi proksimalni kraj; i gdje je prvi proksimalni kraj unutar kratkog ponavljanja i drugi proksimalni kraj je unutar kratkog ponavljanja; i gdje su prvi fragment i drugi fragment jedan uz drugog, te gdje polipeptid izaziva protutijela koja neutraliziraju toksin A i toksin B.
A pharmaceutically acceptable salt of a compound having the structure 
i/ili njihova farmaceutski prihvatljiva sol, tautomer ili stereoizomer.
is H or D, and is H or D, as well as their physiologically acceptable salts and their stereoisomers, enantiomeres or diastereomers in optically pure form. 
L-2-Amino-2,3-dideutero-3-(3,4-dihidroksifenil) propionska kiselina i stereoizomeri, enantiomeri ili diastereomeri u optički čistom obliku kao i njihove fiziološki prihvatljive soli naznačeni time da su za uporabu kao lijek.
Also presented herein is a nucleic acid molecule encoding the isolated antigen binding protein previously described, wherein the nucleic acid molecule is operably linked to a control sequence. 
Nukleinska kiselina koja kodira protutijelo ili fragment protutijela u skladu s jednim od patentnih zahtjeva 1-4, pri čemu je poželjno da je molekula nukleinske kiseline operabilno povezana s kontrolnom sekvencom.
wherein: VL1 is a first immunoglobulin light chain variable domain; 
Vri je varijabilna domena prvog lakog imunoglobulinskog lanca;
Thus the process may further comprise the steps of lyophilising the composition and then, optionally, reconstituting the composition with an aqueous medium. 
Tako se ovaj proces može dalje sastojati od stupnjeva liofilizacije sastava, a zatim, po izboru, rekonstituiranja sastava s vodenim medijem.
Use of tiotropium salts 1 wherein 
Uporaba tiotropijevih soli 1 l naznačena time, da
A solution of 5.45 mg (2.37% w/w) of nebivolol hydrochloride and 3.45 mg (1.5% w/w) of hypromellose was prepared in 440 mg of methanol and 10 mg of water. 
Otopina 5,45 mg (2,37 % w/w) nebivolol hidroklorida i 3,45 mg (1,5 % w/w) hipromeloze pripremljena je u 440 mg metanola i 10 mg vode.
A pharmaceutical dosage form comprising a pharmaceutical composition according to claim 16, wherein the pharmaceutical dosage form comprises 5 mg to 500 mg of compound represented by Formula (III). 
Farmaceutska dozna forma sadržeći farmaceutski sastav prema zahtjevu 11, naznačeno time da farmaceutska dozna forma sadrži 5 mg do 500 mg spoja prikazanog Formulom (III).
Room arrangement according to claim 13, wherein the second fastening means comprise a connecting profile having a first and a second form that fit lower edges of the walls of the room units adjacent to each other, and an element connecting the first and the second form. 
Prostorni sklop u skladu s patentnim zahtjevom 11 ili 12, naznačen time, da druga pričvrsna sredstva sadrže vezni profil (27, 37, 40) koji ima prvi i drugi oblik (34a, 34d) koji pristaje uz donje rubove stijena prostornih jedinica koje se postavljaju neposredno jedna uz drugu, kao i element (35) koji povezuje prvi i drugi oblik.
allowing the antibody to bind to the amyloid protein to form an immunological complex; 
(b) omogućavanja da se protutijelo veže na amiloidni protein kako bi tvorilo imunološki kompleks;
at least one pharmaceutically acceptable excipient. 
(b) barem jednu farmaceutski prihvatljivu pomoćnu tvar.
The pharmaceutical composition according to item 26, wherein the pharmaceutical composition is formulated for administration: orally, intraadiposally, intraarterially, intraarticularly, intracranially, intradermally, intralesionally, intramuscularly, intranasally, intraocularly, intrapericardially, intraperitoneally, intrapleurally, intraprostatically, intrarectally, intrathecally, intratracheally, intratumorally, intraumbilically, intravaginally, intravenously, intravesicularlly, intravitreally, liposomally, locally, mucosally, parenterally, rectally, subconjunctival, subcutaneously, sublingually, topically, transbuccally, transdermally, vaginally, in crèmes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, or via localized perfusion. 
Farmaceutski pripravak prema zahtjevu 5, naznačen time da je farmaceutski pripravak formuliran za davanje: oralno, = intraadipozno, = intraarterijalno, = intraartikularno, = intrakranijalno, = intradermalno, = intralezionalno, intramuskularno, intranazalno, intraokularno, intraperikardijalno, intraperitonealno, intrapleuralno, intraprostatski, intrarektalno, = intratekalno, intratrahealno, = intratumoralno, intralumbalno, intravaginalno, = intravenozno, intravezikularno, intravitralno, liposomalno, lokalno, mukozno, parenteralno, rektalno, pod konjunktivu, subkutano, sublingvalno, topikalno, transbukalno, transdermalno, vaginalno, u kremama, u pripravcima lipida, pomoću katetera, putem ispiranja, putem kontinuirane infuzije, infuzijom, inhalacijom, injekcijom, lokalnim davanjem, ili putem lokalizirane perfuzije.
Movable floating moorage according to claim 3, wherein said winches comprise: 
Pokretno plutajuće sidrište prema zahtjevu 3, naznačeno time što navedena vitla sadrže:
Cognitive function and antipsychotics: An investigation into the efficacy of Isomer A to improve a cognitive deficit induced by sub-chronic PCP in the novel object recognition task 
Kognitivna funkcija i antipsihotici: Ispitivanje učinkovitosti Izomera A u poboljšanju kognitivnog deficita potaknutog sub-kroničnim PCP u zadatku prepoznavanja novog objekta.
B-6-CH3—(OCH2CH2)7—O-Naloxol or a pharmaceutically acceptable salt thereof. 
B-6-CH;-(OCH2CH>);-O-naloksol; ili farmaceutski prihvatljivu sol istih.
The pharmaceutical composition of claim 1, wherein at least 95% of said placental stem cells express CD73, CD105, and CD200. The pharmaceutical composition of claim 1, wherein at least 80% of said placental stem cells express CD200 and OCT-4. 
Izdvojena populacija matičnih stanica iz posteljice u skladu s patentnim zahtjevom 14, naznačena time što navedenih najmanje 80% od navedenih matičnih stanica iz posteljice eksprimira CD200 i OCT-4.
a size of the transformation unit split from the coding unit is determined without considering a size of the at least one prediction unit in the coding unit. 
raščlanjivanje, iz toka bitova, kvantiziranih koeficijenata transformacije barem jedne transformacijske jedinice u jedinici za kodiranje;
R9A and R9B are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and u is an integer from 0 to 5, optionally wherein said compound has the formula: or 
A i R9B su neovisno vodik, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani heteroalkil, nesupstituirani cikloalkil, supstituirani ili nesupstituirani heterocikloalkil, supstituirani ili nesupstituirani aril ili supstituirani ili nesupstituirani heteroaril; i u je cijeli broj od 0 do 5, proizvoljno gdje navedeni spoj ima formulu: Ili
Two bypassing capacitors 78, 79 are provided in parallel, respectively, to resistors 76, 77. 
Dva mosna kondenzatora 78, 79 su spojena u paralelu otpornicima 76, odnosno 77.
The fan assembly of claim 18, wherein the outlet is in the form of a slot. 
Ventilatorski sustav prema zahtjevu 20, gdje je izlaz (98) u obliku utora.
Drugs claimed to be SSRIs are for example fluoxetine, sertraline and paroxetine. 
Lijekovi za koje se tvrdi da su SSRIs su, npr., fluoxetin, sertralin i paroxetin.
Anti-CD20 monoclonal antibodies such as Rituximab, Ofatumumab, Ocrelizumab and TRU-015 from Trubion Pharmaceuticals 
anti-CD20 monoklonalnih antitijela kao što su rituksimab, ofatumumab, ocrelizumab i TRU-015 od tvrtke Trubion Pharmaceuticals;
Compound (I) according to claim 1, 2 or 3 for use according to claim 1, wherein Compound (I) is administered weekly in a dose, calculated as the free base of Compound (I), of about 45 mg/dose. 
(D prema zahtjevu 1, 2 ili 3 za uporabu prema zahtjevu 1, pri čemu se Spoj (I) primjenjuje jednom tjedno u dozi, računato kao slobodna baza Spoja (1), od oko 45 mg/dozi.
Method for tanker (1), preferably parcel tanker, construction, comprising the steps of: 
Postupak za konstruiranje tankera (1), poželjno tankera s odjeljcima, koji obuhvaća sljedeće korake:
A process for preparing the compound of claim 1, the process comprising step (a), of forming compound 3 from compounds 1 and 2: Step (a) 
Postupak dobivanja spoja prema zahtjevu 1, naznačen time što postupak sadrži korak (a), tvorbe spoja 3 iz spoja 1 i Korak (a) i
The granular carbon was impregnated with 60 mg of a 1:1 mixture of propylene glycol and glycerol. 
Granularni ugljik je impregniran sa 60 mg 1:1 smjese propilenglikola i glicerola.
The present invention relates to a compound of formula I: 
HR P20180931 T1 PATENTNI ZAHTJEVI 30 Spoj formule I:
D2O (simplifies upon deuteration), d.a. 
D,O (pojednostavljeno nakon deuterizacije), d.a.
The vaccine according to claim 2, wherein said at least two distinct optimized gag polypeptides comprise the amino acid sequences set forth in SEQ ID NOs:3 and 4, respectively, and/or wherein said at least two distinct optimized pol polypeptides comprise the amino acid sequences set forth in SEQ ID NOs:12 and 13, respectively. 
Cjepivo prema zahtjevu 2, gdje spomenuta barem dva različita optimizirana gag polipeptida sadrže sekvence amino kiselina prikazane u SEQ ID NOs: 3 1 4, respektivno, i/ili gdje spomenuta barem dva različita optimizirana pol polipeptida sadrže sekvence amino kiselina prikazane u SEQ ID NOs: 12 1 13, respektivno.
The compound of claim 1, wherein the compound is selected from the following: 
Spoj prema patentnom zahtjevu 1, naznačen time što je spoj izabran od slijedećih:
contacting a GPR119 agonist in vitro with a mammalian enteroendocrine cell; 
(a) stavljanje u kontakt GPRI 19 agonista in vitro s enteroendokrinom stanicom sisavca; te
The method of claim 1, wherein the immunogenic composition comprises an influenza virus or an antigenic preparation from an H5N1 influenza virus strain. 
Upotreba u skladu s patentnim zahtjevom 38, naznačena time što je navedeni virus influence antigen iz podijeljenog virusa influence ili njegov antigenski pripravak.
The preferred use of a relatively short, low mass substrate or carrier as the aerosol generating means, in close proximity to the short fuel element, also increases aerosol production by minimizing the heat sink effect of the substrate. 
Poželjno korištenje relativno kratkog supstrata ili nosača niske mase kao sredstva za generiranje aerosola, u velikoj blizini sa kratkim gorivim elementom, također povećava proizvodnju aerosola minimiranjem efekta upijanja topline supstrata.
A motor drives the transfer of the extraction module between the closed and opened state. 
Ovaj uređaj nadalje sadržava motor koji drži u pogonu prijelaz modula za ekstrakciju između zatvorenog 1 otvorenog položaja.
The plant cultivation system according to claim 1, which further comprises a plant cultivation support disposed on said nonporous hydrophilic film. 
Sustav za uzgoj biljaka prema bilo kojem od zahtjeva 1 do 6, koji dalje obuhvaća potporu za uzgoj biljaka (4) koja se nalazi na tom neporoznom hidrofilnom sloju (1).
measuring a first value representing the current through a first boost switch (Sb1) of the bridgeless boost converter; 
- < mjerenje prve vrijednosti koja predstavlja struju kroz prvu uzlaznu sklopku (Sbl) uzlaznog pretvarača bez mosta;
The pharmaceutical composition according to Claim 6 wherein the PVP-VA is Kollidon® VA 64. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što je PVP-VA Kollidon& VA 64.
The method of claim 15, wherein R21 is alkyl, cycloalkyl, or cycloalkylalkyl. The method of claim 15, wherein R21 is alkyl, and the alkyl is C1-C4 alkyl. 
Spoj ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 6, naznačen time, da je R21 alkil, C1-C4 alkil, cikloalkil ili cikloalkilalkil.